Alzheimer's Disease

Alzheimer’s Disease – High‑Yield Study Guide for Medical Students

Definition

Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative disorder characterized clinically by insidious onset and gradual decline in memory and other cognitive domains, and pathologically by extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles composed of hyperphosphorylated tau, and resultant synaptic and neuronal loss, predominantly in the hippocampus and association cortices.^[1]

Epidemiology

AD is the most common cause of dementia globally, accounting for approximately 60–70% of cases in older adults. Prevalence increases exponentially with age, particularly beyond 65 years, with a marked rise after 80. Major risk factors include advanced age, positive family history, APOE ε4 genotype, female sex, vascular comorbidities, traumatic brain injury, and low educational attainment (cognitive reserve hypothesis).^[2]

There are sporadic, late‑onset forms (majority) and familial, early-onset forms (mutations in APP, PSEN1, PSEN2) that present before age 65. Sex-specific immune and proteomic differences are an active area of research and may contribute to observed higher prevalence in women.^[2]

Pathophysiology

AD is driven by a complex interaction of abnormal protein processing, synaptic failure, neuroinflammation, and network degeneration. Two hallmark lesions define the disease pathology:

• Amyloid-β (Aβ) plaques: Aβ peptides are generated from amyloid precursor protein (APP) by sequential β- and γ-secretase cleavage. Imbalance between production and clearance leads to aggregation into oligomers and fibrils, forming extracellular plaques that disrupt synaptic function and trigger neuroinflammation.
• Neurofibrillary tangles (NFTs): Hyperphosphorylated tau, a microtubule-associated protein, misfolds and aggregates into intracellular paired helical filaments, forming tangles. This impairs axonal transport, destabilizes microtubules, and correlates strongly with neuronal loss and clinical severity.

The prevailing amyloid cascade hypothesis posits that Aβ accumulation is an early initiating event that sets off downstream tau pathology, synaptic dysfunction, oxidative stress, and neurodegeneration. However, tau burden, network disconnection, and synaptic loss correlate more tightly with cognitive decline than total plaque load, suggesting multifactorial mechanisms.^[3]

Additional mechanistic contributors under active investigation include:

• Neuroinflammation and microglial activation: Dysregulated immune responses and chronic microglial activation contribute to synaptic pruning and neuronal injury.
• Disrupted signaling pathways: Alterations in Wnt/β-catenin and PI3K/Akt pathways affect neuronal survival, synaptic plasticity, and metabolism, and are modulated by microRNA networks and epigenetic mechanisms.^[3]
• Vascular and metabolic factors: Cerebral amyloid angiopathy, impaired glymphatic clearance, insulin resistance, and mitochondrial dysfunction further exacerbate pathology.

Clinical Presentation

AD classically presents with an insidious onset and gradual progression of cognitive decline, most prominently affecting episodic memory. Early symptoms may be subtle and often misattributed to normal aging.

• Early stage (mild cognitive impairment due to AD / mild dementia)
  • Prominent episodic memory impairment: difficulty learning new information, repetitive questioning, misplacing items.
  • Preserved activities of daily living (ADLs) early on, but difficulty with complex instrumental ADLs (finances, driving, managing medications).
  • Mild word-finding difficulty and reduced verbal fluency.
  • Insight may be partially preserved or impaired.
• Middle stage (moderate dementia)
  • Worsening memory deficits, including remote memory.
  • Language impairment (anomia, circumlocutions), impaired comprehension.
  • Visuospatial dysfunction: getting lost in familiar places, difficulty with navigation, dressing apraxia.
  • Impaired executive function: planning, organizing, multi-step tasks.
  • Neuropsychiatric symptoms: apathy, irritability, depression, anxiety, psychosis (delusions, misidentification), and behavioral disturbances such as agitation or wandering.
• Late stage (severe dementia)
  • Severe global cognitive impairment; minimal or no meaningful speech.
  • Loss of independence in basic ADLs (feeding, toileting, bathing).
  • Motor symptoms: gait disturbance, rigidity, myoclonus in some patients.
  • Incontinence, swallowing difficulties, recurrent infections, and high functional dependence.

Less common presentations include atypical variants such as posterior cortical atrophy (visual variant), logopenic variant primary progressive aphasia (language predominant), and frontal variant presentations with early behavioral changes.

Diagnosis

Diagnosis is primarily clinical, supported by cognitive testing and structural and functional imaging, and guided by criteria such as NIA-AA (National Institute on Aging–Alzheimer’s Association).^[4]

Diagnostic Approach

• History and examination
  • Detailed history from patient and collateral informant, focusing on onset, progression, and functional impact.
  • Review medications, comorbidities, vascular risk factors, alcohol/drug use, and family history.
  • Neurological examination to look for focal deficits, parkinsonism, gait disturbance, or atypical signs suggesting alternative diagnoses.
  • Mental status and cognitive examination (MMSE, MoCA, or other standardized tools).
• Laboratory investigations
  • Typical baseline workup to exclude reversible causes of cognitive impairment: CBC, electrolytes, renal and liver function, thyroid function, vitamin B12, folate, syphilis or HIV serology when indicated.
• Neuroimaging
  • MRI brain is the preferred structural imaging modality. It helps exclude secondary causes (tumor, normal pressure hydrocephalus, subdural hematoma, large-vessel stroke) and demonstrates characteristic patterns of atrophy.^[4]
  • Typical MRI findings in AD: medial temporal lobe atrophy (hippocampus, entorhinal cortex), parietal and posterior cingulate atrophy, relative sparing of primary sensory cortices.
  • Advanced MRI techniques (volumetry, diffusion, resting-state connectivity) and specific atrophy patterns may help differentiate Alzheimer’s from other dementias.^[4]
• Biomarkers (where available)
  • CSF biomarkers: decreased Aβ42 (or Aβ42/Aβ40 ratio), increased total tau (t-tau) and phosphorylated tau (p-tau) support underlying AD pathology.
  • PET imaging: FDG-PET showing temporoparietal hypometabolism; amyloid-PET and tau-PET visualize protein deposition and are used mainly in specialized settings or clinical trials.
  • Peripheral biomarkers (e.g., proteomic signatures from PBMCs or plasma) are emerging as minimally invasive tools for early diagnosis and sex-specific risk stratification.^[2]

AD is diagnosed when there is a history and examination showing a major neurocognitive disorder with predominant episodic memory deficits, gradual onset, and progressive decline over months to years, with no better explanation by another brain disease or systemic disorder.

Management

Management of AD is multifaceted, combining pharmacologic and non-pharmacologic strategies, caregiver support, and planning for progressive disability. Current treatments are mainly symptomatic, though emerging data suggest potential disease-modifying effects of some interventions.^[1],[5]

Pharmacologic Management

• Acetylcholinesterase inhibitors (AChEIs)
  • Examples: donepezil, rivastigmine, galantamine.
  • Mechanism: Inhibit acetylcholinesterase, increasing acetylcholine availability in synaptic clefts, thereby enhancing cholinergic neurotransmission in surviving neurons.
  • Indications: Mild to moderate AD; donepezil also approved for severe AD.
  • Benefits: Modest improvements or stabilization in cognition, global function, and activities of daily living; may delay institutionalization in some patients.
  • Emerging literature argues that chronic AChEI therapy may have potential disease-modifying actions, possibly via neurotrophic, synaptic, and neurovascular effects, although definitive proof is pending.^[5]
  • Adverse effects: GI upset (nausea, vomiting, diarrhea), bradycardia, syncope, weight loss, sleep disturbance.
• NMDA receptor antagonist
  • Example: memantine.
  • Mechanism: Non-competitive NMDA receptor antagonist that may reduce excitotoxicity from excess glutamatergic activity.
  • Indications: Moderate to severe AD, often as add-on to an AChEI.
  • Benefits: Modest stabilization or slowing of decline in cognition, behavior, and ADLs.
  • Adverse effects: Dizziness, headache, confusion, constipation; generally well tolerated.
• Disease-modifying monoclonal antibodies (contextual note)
  • Anti-amyloid monoclonal antibodies targeting Aβ (e.g., those aimed at reducing amyloid plaques) have received regulatory attention in some jurisdictions.
  • They require careful patient selection (typically early symptomatic stages), biomarker confirmation, MRI monitoring for ARIA (amyloid-related imaging abnormalities), and shared decision-making given modest effect sizes and safety considerations.
• Management of behavioral and psychological symptoms of dementia (BPSD)
  • First line is non-pharmacologic (environmental adjustment, reassurance, structured routine).
  • For severe agitation, psychosis, or dangerous behaviors unresponsive to non-drug strategies, cautious use of antipsychotics (e.g., low-dose atypicals) may be considered, recognizing increased risks (mortality, stroke).
  • SSRIs can be used for comorbid depression or anxiety; avoid agents with strong anticholinergic properties.
  • Manic or mixed affective symptoms can occur in the context of AD, and require careful differentiation and tailored psychopharmacology (e.g., mood stabilizers or atypical antipsychotics) in collaboration with psychiatry.^[6]

Non-Pharmacologic Management

• Cognitive and functional interventions
  • Cognitive stimulation, reality orientation, and structured activities tailored to patient ability.
  • Occupational therapy for environmental modification and safety (fall prevention, kitchen safety, wandering management).
  • Driving assessment and counseling as disease progresses.
• Exercise and lifestyle
  • Regular aerobic exercise improves neuroplasticity, modulates neurotrophic pathways, enhances cerebral blood flow, and in animal models attenuates Aβ and tau pathology, supporting a role as a potential disease-modifying lifestyle intervention.^[7]
  • Sleep hygiene is critical, as chronic sleep fragmentation exacerbates Aβ accumulation and cognitive decline; experimental models show that altered environmental factors (e.g., temperature stress) can unmask sleep disruption that worsens AD phenotypes.^[8]
  • Management of vascular risk factors (hypertension, diabetes, dyslipidemia, smoking) to reduce further cerebrovascular injury.
• Caregiver support and planning
  • Education for caregivers about disease course, behavioral strategies, and expectations.
  • Early discussions about advance directives, financial and legal planning, and long-term care options.
  • Respite resources and support groups to reduce caregiver burden and burnout.

Key Clinical Pearls

• 1. Memory-predominant, progressive, and insidious: A slowly progressive episodic memory deficit with preserved consciousness and no major focal neurologic deficits is highly suggestive of AD, especially in older adults.
• 2. Rule out reversible causes and mimics: Always screen for depression, medication effects (especially anticholinergics, sedatives), metabolic disturbances, and structural lesions before labeling dementia as Alzheimer’s.
• 3. MRI is essential in the workup: Brain MRI not only excludes alternative structural causes but also reveals characteristic medial temporal and parietal atrophy patterns that support the diagnosis and help differentiate from other dementias.^[4]
• 4. AChEIs and memantine are symptomatic, not curative: Set realistic expectations with patients and families—these drugs modestly slow decline or stabilize function, and treatment should be monitored for both benefit and adverse effects.^[5]
• 5. Think beyond amyloid: Research increasingly emphasizes tau pathology, synaptic failure, neuroinflammation, and epigenetic modulation (e.g., microRNA-mediated regulation of Wnt/β-catenin and PI3K/Akt) as key drivers and therapeutic targets.^[3]
• 6. Behavioral symptoms are common and treatable: Neuropsychiatric features (depression, agitation, psychosis, occasional mania) are integral to AD and require structured non-pharmacologic strategies first, with cautious, targeted psychopharmacology when necessary.^[6]
• 7. Lifestyle interventions matter: Physical activity, vascular risk reduction, cognitive engagement, and sleep optimization have meaningful impact on risk and trajectory, and are central to patient counseling and public health strategies.^[7],[8]
• 8. Emerging biomarkers and precision medicine: CSF, PET, and blood-based markers, along with sex-specific proteomic signatures, are ushering in a biomarker-defined framework for AD, with implications for early diagnosis and targeted therapies.^[2]

Summary

Alzheimer’s disease is the leading cause of dementia, characterized by progressive memory-predominant cognitive decline, driven by amyloid and tau pathology within a broader network of neuroinflammatory and metabolic disturbances. Diagnosis relies on careful clinical assessment, exclusion of reversible causes, and supportive imaging and biomarker findings. While current pharmacologic options (AChEIs and memantine) are mainly symptomatic, emerging disease-modifying strategies, alongside exercise, vascular risk control, and optimized sleep and cognitive engagement, offer a more comprehensive and potentially preventative framework for management and research.